Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Foa

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Frontiers in Oncology|March 21, 2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML StudyAlessandra Iurlo, Daniele Cattaneo, Silvia Artuso, et al.
Blood|January 25, 2002
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaAlessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, et al.
American Journal of Hematology|February 16, 2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor modelStefano Molica, Diana Giannarelli, Andrea Visentin, et al.
Haematologica|August 19, 2024
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL studyDavide Lazzarotto, Marco Cerrano, Cristina Papayannidis, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Frontiers in Oncology|March 21, 2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML StudyAlessandra Iurlo, Daniele Cattaneo, Silvia Artuso, et al.
Blood|January 25, 2002
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaAlessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, et al.
American Journal of Hematology|February 16, 2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor modelStefano Molica, Diana Giannarelli, Andrea Visentin, et al.
Haematologica|August 19, 2024
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL studyDavide Lazzarotto, Marco Cerrano, Cristina Papayannidis, et al.
Pageof 5